Improving HIV and malaria treatment for people in sub-Saharan Africa
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa
Finding safer, more effective ways to treat people living with HIV who also get malaria in sub-Saharan Africa, with special attention to children and adults on the newer HIV drug dolutegravir.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11375254 on NIH RePORTER |
What this research studies
You would be part of work that looks at how HIV drugs like dolutegravir interact with common malaria medicines used in sub-Saharan Africa. The team will measure drug levels, watch for overlapping side effects, and monitor weight and metabolic changes—especially in children on dolutegravir. They will compare commonly used antimalarial combinations to see which give the best protection without harmful interactions. The goal is to guide safer treatment choices for people who have both infections.
Who could benefit from this research
Good fit: Ideal candidates are children and adults living with HIV in sub-Saharan Africa who are taking or starting dolutegravir and who are at risk for or treated for malaria.
Not a fit: People without HIV, those not taking dolutegravir, or those not at risk for malaria (for example living outside malaria-endemic areas) are unlikely to benefit directly.
Why it matters
Potential benefit: This could help clinicians pick HIV and malaria drug combinations that reduce harmful interactions and improve health outcomes for people with both infections.
How similar studies have performed: Previous studies have identified drug interactions between dolutegravir and some antimalarial partner drugs in adults, but prospective pediatric data and direct comparisons across common antimalarial regimens remain limited.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Parikh, Sunil — Yale University
- Study coordinator: Parikh, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.